GoodRx’s Post

Today is my first day at Endpoints News! I can't wait to get fully up and running with this incredibly welcoming team. Please reach out to reconnect, catch me up on what I've missed the past few weeks I've been away, and share your best biotech and health tech news tips! My new email is: [email protected]

📈 Transformations in the U.S. AT CDMO Landscape: Unpacking the Evolution, Layoffs & Closures 🔬 Amid rapid growth, the AT CDMO sector has recently experienced a notable deceleration, prompting discussions on its root causes and potential consequences. Notably, within the past few months, the sector has witnessed a reduction of 2,800 jobs due to restructurings and layoffs. Key insights into this slowdown encompass: COVID Impact: Initial pandemic funding led to excess capacity as vaccination rates dropped. Financial Realities: Market downturn led to closures and job cuts in biotech, impacting CDMOs. Capacity Surge: Investments flooded in, fragmenting the market with more options than clients. Niche Challenges: Cell and Gene Therapy's success with small populations contrasts with slow adoption. Join the conversation on reshaping the sector's path. Let's discuss 'how,' 'why,' and 'what's next' for AT CDMO. Your insights matter as we navigate this transforming landscape together.

Interesting article about the trends, prospects, and challenges associated with the Advanced Therapies (AT) Contract Development Manufacturing Organizations (CDMOs) sector.

📣 Stay up to date with the industry insights, the latest company news, and expert blog posts from BrightGen. Sign up for our newsletter to receive regular updates and exclusive content - straight to your inbox! ➡️ Subscribe here: https://loom.ly/MnIZMEc ⬅️ #Newsletter #TeamBrightGen #SubscribeToday

🔬 Exciting Beginnings: Embarking on a Journey through the U.S. Advanced Therapies (AT) Contract Development Manufacturing Organizations (CDMOs) Landscape, Layoffs and Closures 🔬 We are thrilled to kick off a new series that will take us deep into the heart of the U.S. AT CDMOs sector. Before we dive into the nitty-gritty details of the report, which will include an in-depth exploration of the nation's key biomanufacturing hubs, let's first address a prevailing trend that's been making waves – workforce reductions and facility closures. By opening up this conversation right at the start, we're setting the stage for insightful discussions about where the sector stands today, the journey that has led us here, and the exciting possibilities that lie ahead. Our goal with this series is to cultivate curiosity, engage a diverse range of perspectives, and spark dynamic conversations around this captivating sector. Together, let's unravel its trends, unravel its prospects, and fearlessly tackle its challenges. 💬 Stay tuned for a deep dive into the world of U.S. AT CDMOs – there's much to explore, discuss, and discover! 🌐🔍 Full Article: https://lnkd.in/e6spPtEi #cellandgenetherapy #cdmos #advancedtherapies

I am excited to join the motivated and excellent team of employees, physician thought leaders, researchers, customers, investors, and strategic partner Stryker to help On Target Laboratories to accelerate Surgery 4.0 with our portfolio of advanced intraoperative imaging agents to target and illuminate various cancers during surgery, precision guided therapy. There is a huge unmet need in #digitalsurgery for more real time actionable information to help surgeons see cancer, remove it and improve cancer surgery procedures. We see the benefits to cancer patients being 1) better outcomes, 2) lower costs, and 3) more access to democratized care on a global basis. #digitalsurgery #molecularimaging #medtech #digitalhealth #surgery #cancertreatment #lungcancer #lungcancerawareness #cytalux Ben Lundgren Gwen Watanabe Bernie Haffey Purdue University Stryker Kevin Lobo Andres Rosales Olympus Corporation of the Americas Olympus Corporation Townsend Goddard Fritz French Andy Kessler Joe Mullings The Mullings Group

A few interesting reads for the week.

Happy Thursday #medixnation! I often get asked why we have dedicated so many resources to becoming experts in staffing sub-investigators and principal investigators. My answer - it is required to be good at it! Reason why? We randomly identified 100 Principal Investigators on clinicaltrials.gov and tried to find their information so we could recruit them. Out of the 100 investigators, 39% of them had LinkedIn profiles. Out of those 39 investigators, only 13 of them clearly stated on their profiles that they were principal investigators. The traditional way of staffing candidates is ineffective with regards to investigators which leads to companies straining their talent acquisition resources. Lean on us to help. Give me a call. Zeke Misner | (602)214-2568 | [email protected] | Medix™

Did you get a chance to watch this week's "Cannabis Horizons: Strategies for what's ahead" webinar? Check out the on-demand recording to hear from a panel of leading #Cannabis business advisors, including CohnReznick LLP 's Michael Harlow, as they share their unique industry insights and predictions for what they believe lies ahead for the industry.

🚀 market yourself ✨ Did you find this video helpful? Join our FREE Slack community for biotech job-seekers and get access to biotech recruiters giving more tips and tricks like this. Link below! https://lnkd.in/eFvH-REC #LinkedInHacks #LinkedInTips #JobSeeker #JobSearchHacks #JobSearchTips #BiotechCareers #BiotechJobs #CollaboratoryCareerHub